Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 48% Improvement Relative Risk c19early.org/e Meizlish et al. Aspirin for COVID-19 LATE TREATMENT Is late treatment with aspirin beneficial for COVID-19? PSM retrospective 638 patients in the USA Lower mortality with aspirin (p=0.004) Meizlish et al., American J. Hematology, doi:10.1002/ajh.26102 Favors aspirin Favors control
Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis
Meizlish et al., American Journal of Hematology, doi:10.1002/ajh.26102
Meizlish et al., Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched.., American Journal of Hematology, doi:10.1002/ajh.26102
Jan 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 638 matched hospitalized patients in the USA, 319 treated with aspirin, showing lower mortality with treatment.
risk of death, 47.8% lower, HR 0.52, p = 0.004, treatment 319, control 319, PSM.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Meizlish et al., 21 Jan 2021, retrospective, propensity score matching, USA, peer-reviewed, 22 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: Received: 18 January 2021 Accepted: 18 January 2021 DOI: 10.1002/ajh.26102 RESEARCH ARTICLE Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis Matthew L. Meizlish1 | George Goshua2 | Yiwen Liu3 | Rebecca Fine4 | Kejal Amin5 | Eric Chang2 | Nicholas DeFilippo5,6 | Craig Keating7 | Yuxin Liu2 | Michael Mankbadi4 | Dayna McManus5 | Stephen Y. Wang4 | Christina Price8 Robert D. Bona2 | Cassius Iyad Ochoa Chaar9 | Hyung J. Chun10 | Alexander B. Pine2 | Henry M. Rinder2,11 | Jonathan M. Siner12 Donna S. Neuberg3 | Kent A. Owusu5,13 | Alfred Ian Lee2 1 Yale School of Medicine, New Haven, Connecticut, USA 2 Section of Hematology, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA 3 Dana-Farber Cancer Institute, Boston, Massachusetts, USA 4 Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA 5 Department of Pharmacy, Yale-New Haven Hospital, New Haven, Connecticut, USA 6 School of Pharmacy, University of Connecticut, Storrs, Connecticut, USA 7 Joint Data Analytics Team, Yale New Haven Hospital, New Haven, Connecticut, USA 8 Section of Allergy and Immunology, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA 9 Section of Vascular Surgery, Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA | 10 Section of Cardiology, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA 11 Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA 12 Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA 13 Clinical Redesign, Yale New Haven Health, New Haven, Connecticut, USA Correspondence Alfred Ian Lee, Section of Hematology, Department of Medicine, Yale School of Medicine, New Haven, CT 06510. Email: alfred.lee@yale.edu | Abstract Thrombotic complications occur at high rates in hospitalized patients with COVID19, yet the impact of intensive antithrombotic therapy on mortality is uncertain. We examined in-hospital mortality with intermediate- compared to prophylactic-dose Kent A. Owusu, Department of Pharmacy, Yale-New Haven Hospital, New Haven, CT 06510. Email: kent.owusu@ynhh.org Donna S. Neuberg, Dana-Farber Cancer Institute, Boston, MA 02115. Email: neuberg@ds.dfci.harvard.edu anticoagulation, and separately with in-hospital aspirin compared to no antiplatelet therapy, in a large, retrospective study of 2785 hospitalized adult COVID-19 patients. In this analysis, we established two separate, nested cohorts of patients (a) who received intermediate- or prophylactic-dose anticoagulation (“anticoagulation cohort”, N = 1624), or (b) who were not on home antiplatelet therapy and received Funding information National Institutes of Health, Grant/Award Numbers: HL139116, GM136651, HL142818; Hemostasis and Thrombosis Research Society; American Society of Hematology either in-hospital aspirin or no antiplatelet therapy (“aspirin cohort”, N = 1956). To minimize bias and adjust for confounding factors, we incorporated propensity score matching and multivariable regression utilizing various markers of illness severity and other patient-specific covariates, yielding treatment groups with well-balanced Matthew L. Meizlish, George Goshua, Yiwen Liu and Rebecca Fine contributed equally as first authors. Donna S. Neuberg, Kent A. Owusu and..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit